Advances in digital technologies are promising to revolutionize the delivery of medicine by introducing novel digital therapeutics and digital companion devices for existing therapies, enabling patient-centric clinical decision-making and research, bringing
Point-of-Care to the patient with connected diagnostics, and ultimately impacting patient outcomes. The Inaugural Digital Medicine conference program will convene Digital Health thought leaders to discuss the latest technologies, applications and
implementation strategies in the rapidly evolving field of Digital Medicine.
Final Agenda
<
Monday, March 2
10:30 Conference Program Registration Open
11:45 Organizer’s Opening Remarks
Julia Boguslavsky, Executive Director, Conferences, Cambridge Healthtech Institute
11:50 Chairperson’s Remarks
Thomas Kluz, MS, General Partner, dRx Capital; Head, Healthcare Investing, Qualcomm Ventures
11:55 KEYNOTE PRESENTATION: How Is Wearable-Driven Digital Health Shaping Non-Critical Care?
Ravi Kuppuraj, PhD, CEO, Digital Innovator, Connected Sensing, Philips
Consumer wearable devices have already begun to reshape our general experience by putting people in the driver seat and back in charge of their healthcare – and now the healthcare industry has not only begun to see the same potential with clinical
wearables, but they are becoming more widely adopted and sought after to address real concerns, like providing increased mobility for patients and decreasing costs for healthcare systems in non-critical care settings.
12:15 pm KEYNOTE PRESENTATION: AI and Its Disruptive Implications for Healthcare
Chris Gough, General Manager, Health & Life Sciences, Intel Corporation
In this talk, we will explore the disruptive potential of AI for the healthcare industry. This will include market insights, real-world examples of deployments and use cases in healthcare from around the world, and practical guidance for how to prepare
your organization to take advantage of these capabilities.
12:35 KEYNOTE PRESENTATION: Forging New Paths for the Digital Revolution in Healthcare
Charles Mathews, Principal, ClearView Healthcare Partners
Digital health technology is not only fostering the development and deployment of novel tools that provide innovative clinical information and interventions but it is also raising questions about commercialization, reimbursement, and value creation.
In this session, we will discuss the unique ways in which digital health can be leveraged (e.g., prevention, disease management, therapeutic, etc.) and weigh the trade-offs between business models (e.g., payer reimbursed, B2B, etc.). We will also
provide insights into strategies that harness the unique nature of digital tools and create a virtuous cycle that fosters innovation.
12:55 KEYNOTE PANEL DISCUSSION: How Is “Big Tech” Implementing Digital Health?
Moderator: Thomas Kluz, MS, General Partner, dRx Capital; Head, Healthcare Investing, Qualcomm Ventures
Panelists: Chris Gough, General Manager, Health & Life Sciences, Intel Corporation
Ravi Kuppuraj, PhD, CEO, Digital Innovator, Connected Sensing, Philips
Charles Mathews, Principal, ClearView Healthcare Partners
Joe Ritchie, Chief Commercial Officer, SensoryData Corporation
1:30 Digital Health Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own
2:05 Session Break
2:30 Chairperson’s Remarks
Joris van Dam, PhD, Head, Digital Therapeutics, Novartis Institutes for BioMedical Research
2:35 Digital Therapeutics in Pharma
Joris van Dam, PhD, Head, Digital Therapeutics, Novartis Institutes for BioMedical Research
The Digital Therapeutics Alliance often refers to digital therapeutics as “a new class of medicine.” In this talk, we will explore the opportunities and challenges of integrating digital therapeutics as a new therapeutic class within a
more traditional medicines portfolio based on our experience at Novartis and based on our successes and challenges in our partnership with Pear Therapeutics.
3:00 Pharma: The Five Questions You Need to Be Able to Answer about Your Digital Therapeutic
Geoff McCleary, Director, Digital Health & Therapeutics, PricewaterhouseCoopers
3:25 Prescription Digital Therapeutics: Establishing a New Therapeutic Class
Alex Waldron, Chief Strategy Officer, Pear Therapeutics
Prescription digital therapeutics (PDTs) are a new modality of therapeutic providing efficacy in many dis-ease areas previously untreated, or only partially treated.
3:50 Digital Medicine Extends to Peer Support
Adam Kaufman, PhD, President & CEO, Canary Health
So many of the outcomes we care about to improve health and impact costs are driven by individuals’ behaviors, emotions, relationships, lifestyle and system navigation. This talk will highlight how evidence-based, digital, peer-to-peer support
groups are extending care models to engage individuals with chronic conditions and cost-effectively enable peers to support each other, often in ways that complement traditional provider-driven care.
4:15 Q&A with the Speakers
4:25 Refreshment Break and Transition to Plenary Keynote
4:35 Welcome Remarks
Cindy Crowninshield, RDN, LDN, HHC, Executive Event Director, Cambridge Healthtech Institute
4:45 PLENARY KEYNOTE INTRODUCTION
Thomas Westerling-Bui, PhD, Senior Scientist, Regional Business Development, Aiforia
5:00 PLENARY KEYNOTE PRESENTATION: High-Performance Medicine
Eric Topol, MD, Founder and Director, Scripps Research Translational Institute (SRTI); Author, Deep Medicine: How Artificial
Intelligence Can Make Healthcare Human Again
6:00 Grand Opening Reception in the Exhibit Hall with Poster Viewing, Speed Networking, Book Signing, and Meetup Group
7:30 End of Day
Tuesday, March 3
7:30 am Registration Open and Morning Coffee
8:00 Organizer’s Remarks
Julia Boguslavsky, Executive Director, Conferences, Cambridge Healthtech Institute
8:05 Chairperson’s Remarks
Geoff McCleary, Director, Digital Health & Therapeutics, PricewaterhouseCoopers
8:10 NEW KEYNOTE PRESENTATION: Digital Health Technologies for Mental Health
Yu-Feng (Yvonne) Chan, MD, PhD, Senior Director, Medical Affairs for Digital Medicine, Otsuka
We're in the midst of a mental health crisis in the US and worldwide, with 20% of US adults experiencing some form of mental illness and an acute shortage of mental health professionals results in severe unmet needs and high economic costs. Digital
health technologies may offer new options for mental health treatment. This talk explores whether this technology enhanced, multi-stakeholder, multi-disciplinary approach could help drive better patient outcomes.
8:30 KEYNOTE PRESENTATION: The Experimental Science behind Empowering Teams
Matt Lasmanis, Vice President, Technology, GlaxoSmithKline
How do you make large organizations more agile, customer-centric and flexible? There are myriad answers, and GSK is using their science focused approach to guide the way. Matt Lasmanis, VP of Pharma US Tech, is leading the transformation of the GSK
tech culture, empowering his teams to achieve outcomes with clarity over certainty. In the presentation, Matt will discuss: 1) leading experiment-driven, data and product-oriented teams and avoiding non-failure driven culture, 2) empowering teams
to make decisions closer to the ground, 3) shifting mindset of teams to be more agile and business-minded.
8:50 Making Personalized Healthcare a Reality: The Potential of Digital Health Technologies
Mary
Beattie, MD, MAS, Global Group Medical Director, Personalized Health Care,
Roche/Genentech
At Roche, we are working collaboratively to develop Digital Health solutions that aim to improve patient outcomes at each stage of the care continuum. I will discuss how these initiatives can enhance patient care, from early diagnosis to remote monitoring.
Digital Health solutions are central to our Personalized Healthcare vision.
9:10 KEYNOTE PANEL DISCUSSION: How Is “Big Pharma” Implementing Digital Health?
Moderator: Geoff McCleary, Director, Digital Health & Therapeutics, PricewaterhouseCoopers
Panelists:
Joris van Dam, PhD, Head, Digital Therapeutics, Novartis Institutes for BioMedical Research
Mary Beattie, MD, MAS, Global Group Medical Director, Personalized Health Care, Roche/Genentech
Yu-Feng (Yvonne) Chan, MD, PhD, Senior Director, Medical Affairs for Digital Medicine, Otsuka
9:40 Refreshment Break in the Exhibit Hall with Poster Viewing, Speed Networking, Book Signing, and Meetup Group
10:40 Chairperson’s Remarks
Dan Karlin, MD, CEO, HealthMode
10:45 Digital Measurement in Clinical Trials: Fitting the Tool to the Question
Dan Karlin, MD, CEO, HealthMode
Measurement in clinical trials is progressing from intermittent and imprecise, to highly granular and continuous. Making sense of this progression requires understanding the past/current means of measurement, the process for moving toward better measures,
and having a vision for what the future might hold. Using four examples from our work, Dr. Karlin will address past, present, and potential future states in cough, bowel habits, agitation, pain, and performance status in oncology.
11:05 Digital Measures for Neurological Disorders
Ray Dorsey, MD, David M. Levy Professor, Neurology; Director, CHeT, University of Rochester
Current measures for neurological disorders are subjective, episodic, and insensitive. Consequently, we have no highly effective therapies for Alzheimer’s disease, the most effective therapy for Parkinson’s is more than 50 years old, and
many rare neurological disorders have no treatments at all. Smartphones, wearable sensors, and newer technologies can provide objective, frequent, sensitive assessments in real-world settings. The result could accelerate development of new drugs
for the world’s leading source of disability and improved care for millions.
11:25 Uncovering the Potential of Wearable Devices for Identifying and Monitoring Neurological Events and Disease Progression
Jian Yang, MD, Senior Director, Digital Health, Eli Lilly
This presentation will dive into findings from research on recent digital neurology research conducted with consumer devices and sensors. It will share how these devices could eventually equip consumers with tools to support early disease detection
and progression and share key insights on how these may apply to other chronic conditions.
11:45 The Pursuit of Novel Digital Endpoints: What Is It? Learning & Considerations
Michelle Crouthamel, PhD, MSc, DBA, Director, Digital Health & Innovation, AbbVie
12:05 pm Delivering a Digital Biomarker for a Regulated Trial in Rare Disease
Dudley Tabakin, CEO, VivoSense
VivoSense is the first analytics company to develop novel digital biomarkers from wearable sensor data which constitute primary and secondary clinical endpoints in regulated international pharmaceutical trials. Several of these studies are in rare
disease indications, and have reached the open-label phase of development at top-ten pharma.
12:35 Session Break
12:40 Digital Health Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own
1:20 Refreshment Break in the Exhibit Hall with Poster Viewing, Speed Networking, Book Signing, and Meetup Group
2:00 Breakout Discussions in the Exhibit Hall (please click here for details)
3:00 Transition to Conference Programs
3:15 Chairperson’s Remarks
Michael Benecky, PhD, Senior Director, Global Regulatory Affairs, Precision & Digital Medicine, GlaxoSmithKline
3:20 Regulatory Considerations during Mobile Medical App Development for Commercial and Clinical Trial Use
Michael Benecky, PhD, Senior Director, Global Regulatory Affairs, Precision & Digital Medicine, GlaxoSmithKline
Mobile medical apps are defined as medical devices from their intended use. Mobile medical app regulation is health risk-based to balance patient safety and barriers to technological innovation. Medical device patient risk analysis is a critical prerequisite
prior to sensor/app inclusion within a clinical trial. Key components of quality management systems for mobile medical apps include: software requirements/specifications, user acceptance testing, software postmarket surveillance, software version
control and medical device adverse event reporting.
3:50 Opportunities and Challenges in the Digital Landscape of Regulated and Non-Regulated Products
Darin Oppenheimer, Executive Director, Regulatory Affairs & Digital Health Solutions, Merck
Digital Health continues to make inroads in various applications within the pharmaceutical industry. From standalone mobile apps, connected products, as well as applications in clinical trials, the opportunities are evolving as we speak. The regulatory
landscape for digital solutions also continues to evolve, as MoH’s such as FDA and EMA continue to put out guidance and recommendations on how best to manage this rapidly changing area, taking risk into account. In this talk, we will lay
the foundation from regulatory perspective on the past, present, and future of digital health solutions.
4:20 Regulatory Strategies for Digital Medicine
Andrew C. Fish, JD, Chief Strategy Officer, AdvaMed Center for Digital Health
4:50 Spring Fling Celebration in the Exhibit Hall with Poster Viewing, Speed Networking, Book Signing, and Meetup Group
6:00 End of Day
Wednesday, March 4
6:45 am Registration Open
7:00 BREAKFAST PANEL DISCUSSION: The Time is NOW: Creating Meaningful Change for Women in the Workplace (Sponsorship Opportunity Available)
(please see Women in Science page for details)
Moderator:
Robin Toft, Author of WE CAN, The Executive Woman’s Guide to Career Advancement; Founder and Chairman, Toft Group Executive Search
Panelists: Camille Samuels, MBA, Partner, Venrock
Paul Hastings, President and CEO, Nkarta Therapeutics, Inc
Teresa L. Wright, MD, Staff Physician, Medicine, San Francisco Veterans Administration
8:00 Chairperson’s Remarks
Ashish Atreja, MD, MPH, Assistant Professor, Chief Innovation Officer, Medicine, Icahn School of Medicine at Mount Sinai
8:05 A Platform Approach to Digital Transformation and Real-World Evidence
Ashish Atreja, MD, MPH, Assistant Professor, Chief Innovation Officer, Medicine, Icahn School of Medicine at Mount Sinai
The practice of medicine is exponentially evolving. This evolution is fueled by value-based transformation and incentives that are aligning for continuous, proactive care, within and outside the four walls of the hospitals. To address this need, the
new generation of startups is leveraging disciplines like data science, informatics, digital medicine, genomics, and AI; but this is creating a problem of plenty. In spite of more than 350,000 mobile apps for healthcare, less than 4% of patients
are recommended apps by providers today.
8:25 NEW: Wearable Technologies for Remote Data Collection in Clinical Trials
Elena Izmailova, PhD, CSO, Koneksa Health
8:45 Unleashing the Potential of ML in Clinical Development
Kyle Holen, MD, Head, Development Design Center, AbbVie
Kyle will discuss the latest techniques his team has been using in attempts to solve some of the biggest challenges in drug development today, including site selection challenges, patient dropouts, and placebo enrollment. He will share some of the
successes and failures along their journey as well as a future look at new areas where machine learning can help us design and execute on more efficient and rapid clinical trials.
9:05 Importance of Reorientation of Digital Medicine Product and Service Designs to Focus on the Patient as an Individual Consumer – Consumer-Oriented Patient Engagement Strategies
Raj Pallapothu, Professor & Health Care Tech Industry Lead, University of Texas, Dallas
This presentation will cover: 1) new-generation digital biomarkers; 2) wearables in clinical trials; 3) evolving connected platforms and services (patient as consumer); 4) emerging digital study design and underlying study protocol changes; and 5)
growing need for adaptive clinical trials and underlying importance aligned with consumerization.
9:25 Q&A with the Speakers
9:40 Refreshment Break in the Exhibit Hall with Poster Viewing, Speed Networking, Book Signing, and Meetup Group
10:40 Chairperson’s Remarks
Asif Dhar, Chief Health Informatics Officer, Principal, Deloitte Consulting LLP
10:45 KEYNOTE PRESENTATION: Harmonizing Healthcare Innovation for Better, Faster Transformation
Leigh Anderson, President of Performance Services, Premier, Inc.
Leigh Anderson, Premier’s President of Performance Services, will address the evolving healthcare ecosystem and how technological innovation including the application of artificial intelligence and machine learning must occur using a collaborative
framework in order to quickly meet our goals of providing more coordinated, patient-centric and high-quality care.
11:10 KEYNOTE PRESENTATION: Smart Health Communities
Asif Dhar, Chief Health Informatics Officer, Principal, Deloitte Consulting LLP
This presentation will cover how digital disruptions are going to completely change the way we live and empower communities to battle disease and create abundant wellness.
11:35 KEYNOTE PANEL DISCUSSION: Building Digital Healthcare
Moderator: Asif Dhar, Chief Health Informatics Officer, Principal, Deloitte Consulting LLP
Panelists: Leigh Anderson, President of Performance Services, Premier, Inc.
John Mattison, MD, Chief Medical Information Officer, emeritus, Kaiser Permanente
Claus Jensen, PhD, Chief Digital Officer & Head of Technology, Memorial Sloan Kettering Cancer Center
Laura Yecies, Digital Health Entrepreneur, Advisor, RX.Health, Akili Interactive
12:15 pm Session Break
12:50 Digital Health Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own
1:20 Refreshment Break in the Exhibit Hall with Last Chance Poster Viewing, Speed Networking, Book Signing, and Meetup Group
2:00 Chairperson’s Remarks
Adrian Chernoff, Former Worldwide Vice President, Global Head of Research and Development, Johnson and Johnson
2:05 Wearables and Health
Michael Snyder, PhD, Stanford W. Ascherman Professor & Chair, Department of Genetics; Director, Center for Genomics & Personalized Medicine, Stanford University
We have been using smart watches and continuous glucose monitoring to track people’s health and find early signs of disease.
2:25 Patient-Centricity, the Future to Enabling Digital Health
Adrian Chernoff, Former Worldwide Vice President, Global Head of Research and Development, Johnson and Johnson
Payers, providers and patients are beginning to encounter changes to the healthcare landscape with the introduction of new digital tools. As we shift into this new reality a key component will be to put the patient at the center shifting the relationship
dynamics in how we deliver digital applications and build digital ecosystems to meet the growing needs of patients at any stage of care from healthcare, home care or self-care.
2:45 The Power and Potential of VR Medicine
Ramsay Brown, Director, Product Science, AppliedVR
With over 30 years of clinical research, the healthcare industry has embraced virtual reality (VR). Today, rapidly advancing mobile technology yielding ever more immersive experiences at a lower cost, is driving the use of VR beyond research environments
into the clinical trenches and patient homes. Therapeutic VR is a promising new modality with the potential to treat serious and debilitating medical conditions, including pain - one of the most widely studied of all disease areas to date - by
delivering a low-risk, non-pharmacological intervention.
3:05 Virtual Worlds, Real Results: How VR Is Transforming Healthcare
Howard Rose, MEd, CEO & Co-Founder, Firsthand Technology
Howard will share the compelling evidence from clinical applications of VR therapy. VR's potential to induce deep changes in the brain unlocks new therapies for challenging conditions and populations. Propelled by the tsunami of consumer technologies,
VR is poised to be the engine for personalized medicine that will fundamentally transform our health and the healthcare industry.
3:25 Close of Conference